R. Alves, M. Fernandes, I. Figueiredo, D. Borges, Filipa Louenço
{"title":"老年心力衰竭患者的再诊断。回顾性研究","authors":"R. Alves, M. Fernandes, I. Figueiredo, D. Borges, Filipa Louenço","doi":"10.4081/GC.2020.9106","DOIUrl":null,"url":null,"abstract":"Heart failure is a major cause of morbidity and mortality worldwide. The prevalence increases with age and usually progresses, leading to repeated hospital admissions and significant symptom burden for patients. The correct management of these patients may decrease readmissions and increase quality of life. Our aim is to compare elderly patients with and without 1-year readmissions in an internal medicine ward, particularly in terms of mortality. Retrospective study, consulting patient’s clinical records, with a diagnosis of heart failure. The patients were characterized and divided in groups: with (wR) and without readmission (woR) within 1 year. Mortality was the primary outcome. Eighty-nine patients were included; 60 woR and 29 wR. There was no gender difference between groups, the wR group had older patients. The most frequent comorbidities included atrial fibrillation, hypertension and chronic renal failure stage 3 or higher. The most frequent cause of hospitalization was heart failure due to insufficient therapy or natural progression of the disease. The etiology of heart failure was mainly hypertensive and ischemic. The wR group had more patients classified as NYHA >III . In relation to the primary outcome; mortality at 12 months was higher in the group with repeated admissions . The characterization of this population allows us to highlight the causes of decompensation and to review medication in order to increase the quality of life. Introduction and objectives Heart failure is defined as a clinical syndrome comprised of typical symptoms including breathlessness, fatigue and peripheral edema, among others, many related to congestion and fluid overload resulting from structural or functional cardiac abnormality.15 Heart failure is currently divided in three subgroups; heart failure with decreased ejection fraction (EF) (EF<40%), heart failure with intermediate EF (EF 40-49%) which currently has no clinical implications but is a target for research, and finally heart failure with preserved EF (EF>50%).5 Heart failure severity is classified according to symptom severity and exercise tolerance using the New York Heart Academy functional classification. Heart failure is a major cause of morbidity and mortality worldwide; it affects about 2% of the adult population, and the lifetime risk of developing heart failure is one in five.1-3 The prevalence increases with age and it is associated with highly prevalent comorbidities such as hypertension, coronary artery disease, cardiomyopathies and valve disease. As a result of ageing of the population the prevalence of heart failure is projected to increase by 25% in the next 20 years.1,3 Mortality remains high despite improvements, with a rate of 6-7% in chronic heart failure and 25% in patients with acute decompensations and hospital admission.1,3,69 According to European guidelines,5 heart failure with reduced EF treatment is based on neuro-hormonal antagonists and devices to block the remodeling of the heart and improve outcomes and diuretics for relief of congestion.3,5 Neuro-hormonal antagonists include ACE inhibitors; angiotensin receptor blockers (ARBs); β blockers; mineralocorticoid receptor antagonists (MRAs); and, based on more recent data, angiotensin receptor blocker neprilysin inhibitors (ARNIs). These interventions have been shown to improve outcomes.5 Heart failure has complex symptoms associated, with uncertain prognosis, with multiple hospital admissions to control episodes of decompensation.4 Heart failure usually progresses, and is many times, a fatal condition, which provides much symptom burden for patients. Materials and Methods We describe a retrospective study, consulting a patient’s clinical records, hospital population over 65 years of age with a diagnosis of heart failure, hospitalized in the year of 2017, in an internal medicine ward in a tertiary hospital. Patients were in Lisbon. We divided the population into 2 groups with (wR) and without (woR) hospital readmission within 1 year and were compared regarding the patient’s gender, age, level of autonomy, comorbidities and reason for hospitalization. The etiology of heart disease, BNP assay and echocardiogram were characterized. The primary outcome was death at 12 months.","PeriodicalId":30930,"journal":{"name":"Geriatric Care","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4081/GC.2020.9106","citationCount":"0","resultStr":"{\"title\":\"Readmissions in elderly patients with heart failure. A retrospective study\",\"authors\":\"R. Alves, M. Fernandes, I. Figueiredo, D. Borges, Filipa Louenço\",\"doi\":\"10.4081/GC.2020.9106\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Heart failure is a major cause of morbidity and mortality worldwide. The prevalence increases with age and usually progresses, leading to repeated hospital admissions and significant symptom burden for patients. The correct management of these patients may decrease readmissions and increase quality of life. Our aim is to compare elderly patients with and without 1-year readmissions in an internal medicine ward, particularly in terms of mortality. Retrospective study, consulting patient’s clinical records, with a diagnosis of heart failure. The patients were characterized and divided in groups: with (wR) and without readmission (woR) within 1 year. Mortality was the primary outcome. Eighty-nine patients were included; 60 woR and 29 wR. There was no gender difference between groups, the wR group had older patients. The most frequent comorbidities included atrial fibrillation, hypertension and chronic renal failure stage 3 or higher. The most frequent cause of hospitalization was heart failure due to insufficient therapy or natural progression of the disease. The etiology of heart failure was mainly hypertensive and ischemic. The wR group had more patients classified as NYHA >III . In relation to the primary outcome; mortality at 12 months was higher in the group with repeated admissions . The characterization of this population allows us to highlight the causes of decompensation and to review medication in order to increase the quality of life. Introduction and objectives Heart failure is defined as a clinical syndrome comprised of typical symptoms including breathlessness, fatigue and peripheral edema, among others, many related to congestion and fluid overload resulting from structural or functional cardiac abnormality.15 Heart failure is currently divided in three subgroups; heart failure with decreased ejection fraction (EF) (EF<40%), heart failure with intermediate EF (EF 40-49%) which currently has no clinical implications but is a target for research, and finally heart failure with preserved EF (EF>50%).5 Heart failure severity is classified according to symptom severity and exercise tolerance using the New York Heart Academy functional classification. Heart failure is a major cause of morbidity and mortality worldwide; it affects about 2% of the adult population, and the lifetime risk of developing heart failure is one in five.1-3 The prevalence increases with age and it is associated with highly prevalent comorbidities such as hypertension, coronary artery disease, cardiomyopathies and valve disease. As a result of ageing of the population the prevalence of heart failure is projected to increase by 25% in the next 20 years.1,3 Mortality remains high despite improvements, with a rate of 6-7% in chronic heart failure and 25% in patients with acute decompensations and hospital admission.1,3,69 According to European guidelines,5 heart failure with reduced EF treatment is based on neuro-hormonal antagonists and devices to block the remodeling of the heart and improve outcomes and diuretics for relief of congestion.3,5 Neuro-hormonal antagonists include ACE inhibitors; angiotensin receptor blockers (ARBs); β blockers; mineralocorticoid receptor antagonists (MRAs); and, based on more recent data, angiotensin receptor blocker neprilysin inhibitors (ARNIs). These interventions have been shown to improve outcomes.5 Heart failure has complex symptoms associated, with uncertain prognosis, with multiple hospital admissions to control episodes of decompensation.4 Heart failure usually progresses, and is many times, a fatal condition, which provides much symptom burden for patients. Materials and Methods We describe a retrospective study, consulting a patient’s clinical records, hospital population over 65 years of age with a diagnosis of heart failure, hospitalized in the year of 2017, in an internal medicine ward in a tertiary hospital. Patients were in Lisbon. We divided the population into 2 groups with (wR) and without (woR) hospital readmission within 1 year and were compared regarding the patient’s gender, age, level of autonomy, comorbidities and reason for hospitalization. The etiology of heart disease, BNP assay and echocardiogram were characterized. The primary outcome was death at 12 months.\",\"PeriodicalId\":30930,\"journal\":{\"name\":\"Geriatric Care\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.4081/GC.2020.9106\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Geriatric Care\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4081/GC.2020.9106\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Geriatric Care","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4081/GC.2020.9106","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Readmissions in elderly patients with heart failure. A retrospective study
Heart failure is a major cause of morbidity and mortality worldwide. The prevalence increases with age and usually progresses, leading to repeated hospital admissions and significant symptom burden for patients. The correct management of these patients may decrease readmissions and increase quality of life. Our aim is to compare elderly patients with and without 1-year readmissions in an internal medicine ward, particularly in terms of mortality. Retrospective study, consulting patient’s clinical records, with a diagnosis of heart failure. The patients were characterized and divided in groups: with (wR) and without readmission (woR) within 1 year. Mortality was the primary outcome. Eighty-nine patients were included; 60 woR and 29 wR. There was no gender difference between groups, the wR group had older patients. The most frequent comorbidities included atrial fibrillation, hypertension and chronic renal failure stage 3 or higher. The most frequent cause of hospitalization was heart failure due to insufficient therapy or natural progression of the disease. The etiology of heart failure was mainly hypertensive and ischemic. The wR group had more patients classified as NYHA >III . In relation to the primary outcome; mortality at 12 months was higher in the group with repeated admissions . The characterization of this population allows us to highlight the causes of decompensation and to review medication in order to increase the quality of life. Introduction and objectives Heart failure is defined as a clinical syndrome comprised of typical symptoms including breathlessness, fatigue and peripheral edema, among others, many related to congestion and fluid overload resulting from structural or functional cardiac abnormality.15 Heart failure is currently divided in three subgroups; heart failure with decreased ejection fraction (EF) (EF<40%), heart failure with intermediate EF (EF 40-49%) which currently has no clinical implications but is a target for research, and finally heart failure with preserved EF (EF>50%).5 Heart failure severity is classified according to symptom severity and exercise tolerance using the New York Heart Academy functional classification. Heart failure is a major cause of morbidity and mortality worldwide; it affects about 2% of the adult population, and the lifetime risk of developing heart failure is one in five.1-3 The prevalence increases with age and it is associated with highly prevalent comorbidities such as hypertension, coronary artery disease, cardiomyopathies and valve disease. As a result of ageing of the population the prevalence of heart failure is projected to increase by 25% in the next 20 years.1,3 Mortality remains high despite improvements, with a rate of 6-7% in chronic heart failure and 25% in patients with acute decompensations and hospital admission.1,3,69 According to European guidelines,5 heart failure with reduced EF treatment is based on neuro-hormonal antagonists and devices to block the remodeling of the heart and improve outcomes and diuretics for relief of congestion.3,5 Neuro-hormonal antagonists include ACE inhibitors; angiotensin receptor blockers (ARBs); β blockers; mineralocorticoid receptor antagonists (MRAs); and, based on more recent data, angiotensin receptor blocker neprilysin inhibitors (ARNIs). These interventions have been shown to improve outcomes.5 Heart failure has complex symptoms associated, with uncertain prognosis, with multiple hospital admissions to control episodes of decompensation.4 Heart failure usually progresses, and is many times, a fatal condition, which provides much symptom burden for patients. Materials and Methods We describe a retrospective study, consulting a patient’s clinical records, hospital population over 65 years of age with a diagnosis of heart failure, hospitalized in the year of 2017, in an internal medicine ward in a tertiary hospital. Patients were in Lisbon. We divided the population into 2 groups with (wR) and without (woR) hospital readmission within 1 year and were compared regarding the patient’s gender, age, level of autonomy, comorbidities and reason for hospitalization. The etiology of heart disease, BNP assay and echocardiogram were characterized. The primary outcome was death at 12 months.